Urinary thymine dimers and 8-oxo-2'-deoxyguanosine in psoriasis

FEBS Lett. 1999 Nov 5;460(3):549-53. doi: 10.1016/s0014-5793(99)01402-7.

Abstract

Psoralen in conjunction with UVA (PUVA) is perhaps the most effective treatment for psoriasis. It is, however, a risk factor for skin cancer in these patients and there is a need to develop non-invasive assays reflective of treatment-induced DNA damage. We report here the assessment of two important lesions, thymine dimer (T<>T) and 8-oxo-2'-deoxyguanosine (8-OHdG), in the urine of psoriasis patients. It was found that, once corrected for urine concentration, the psoriatic group had significantly higher (P<0. 0001) urinary levels of thymine dimers compared to the control group. No significant differences in urinary 8-OHdG levels were noted between the psoriatic, atopic dermatitis and control groups. Therefore biomonitoring of therapy from the very start with this simple and non-invasive assay could perhaps be an effective measure of the risk involved with the treatment allowing optimization for minimal-risk therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 8-Hydroxy-2'-Deoxyguanosine
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • DNA Damage / genetics
  • Deoxyguanosine / analogs & derivatives*
  • Deoxyguanosine / urine
  • Female
  • Humans
  • Male
  • Middle Aged
  • PUVA Therapy / adverse effects
  • Poly T / therapeutic use
  • Psoriasis / drug therapy
  • Psoriasis / urine*
  • Pyrimidine Dimers / urine*
  • Risk Assessment

Substances

  • Pyrimidine Dimers
  • Poly T
  • 8-Hydroxy-2'-Deoxyguanosine
  • Deoxyguanosine